The firm points out that in the Phase 2 VENTURE trial, weekly subcutaneous VK2735 achieved up to 14.7% weight loss in just 13 weeks in obese patients. It thinks Viking has an attractive alternative in ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Novo Nordisk (NVO) shares fell nearly 7% premarket on Monday, the most since December, after the drugmaker said its ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...

Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue ...

Arrowhead (ARWR) announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ...

The following is a summary of “Effect of spesolimab on sustained disease control in patients with generalized pustular ...

The FDA has accepted for review the BLA for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.

Too many ab workouts could be making belly fat worse instead of better. Why overtraining your core can lead to weight gain ...

The study used innovative technology that maps RNA molecules which are the basis for translating the genome into proteins.

We all know that being overweight is bad for your health. Carrying excess fat is a risk factor for heart disease, Type 2 diabetes, a range of cancers and an increased chance of an early death. The ...

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...